GOSS Since 2019 Annualized Return and Average Annual Return

GOSS Average Annual Return Chart Since 2019
Growth of $10,000.00
Without Dividends Reinvested Into GOSS

Also see:
• GOSS stock yearly return 2020
• GOSS stock yearly return 2021
• GOSS stock yearly return 2022
• GOSS stock yearly return 2023
• GOSS stock yearly return 2024
• GOSS stock yearly return 2025
• GOSS YTD return
Average Annual Return Benchmarks
Compare GOSS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
GOSS Share Performance
GOSS Average Annual Return Table Since 2019
Start date: 02/11/2019
End date: 07/17/2026
Start price/share: $18.36
End price/share: $0.17
Dividends collected/share: $0.00
Total return: -99.07%
GOSS Average Annual Return: -46.75%
Starting investment: $10,000.00
Ending investment: $92.58
Years: 7.43


GOSS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Gossamer Bio Inc
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. The GOSS average annual return since 2019 is shown above.

The Average Annual Return on the GOSS average annual return since 2019 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether GOSS average annual return since 2019 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the GOSS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
GOSS Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree GOSS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Gossamer Bio (GOSS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

GOVX Average Annual Return
GRCE Average Annual Return
GRDN Average Annual Return
GRDX Average Annual Return
GRI Average Annual Return
GTBP Average Annual Return
GUTS Average Annual Return
GYRE Average Annual Return
HAE Average Annual Return
HALO Average Annual Return
More Healthcare companies »
 

GOSS Average Annual Return Since 2019 | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.